Head-To-Head Analysis: Fresenius SE & Co. (OTCMKTS:FSNUY) & Bioqual (OTCMKTS:BIOQ)

Fresenius SE & Co. (OTCMKTS:FSNUY) and Bioqual (OTCMKTS:BIOQ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Risk and Volatility

Fresenius SE & Co. has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Dividends

Fresenius SE & Co. pays an annual dividend of $0.19 per share and has a dividend yield of 1.4%. Bioqual pays an annual dividend of $0.50 per share and has a dividend yield of 1.3%. Fresenius SE & Co. pays out 35.8% of its earnings in the form of a dividend. Bioqual pays out -42.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Earnings and Valuation

This table compares Fresenius SE & Co. and Bioqual”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.53	26.19
Bioqual	$48.87 million	0.73	-$1.05 million	($1.18)	-33.90

Fresenius SE & Co. has higher revenue and earnings than Bioqual. Bioqual is trading at a lower price-to-earnings ratio than Fresenius SE & Co., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Fresenius SE & Co. and Bioqual, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius SE & Co.	0	0	2	1	3.33
Bioqual	0	0	0	0	0.00

Profitability

This table compares Fresenius SE & Co. and Bioqual’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius SE & Co.	5.09%	9.33%	4.31%
Bioqual	-2.14%	-2.90%	-1.87%

Summary

Fresenius SE & Co. beats Bioqual on 12 of the 13 factors compared between the two stocks.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.